|
|
|
|
Time-Released Interferon Locteron Study Enrollment Completed
- EASL: Randomized Trial Comparing Systemic and Local Reactions to Controlled-release Interferon Alpha2b and Pegylated-interferon Alpha2b in Hepatitis C Patients Who Failed Prior Treatment - (05/07/09) Co Press Release: Biolex presents...
|
|
|
Scientists Peg 12-Peptide Cluster as Primary Toxin in Alzheimers Disease
A cluster of 12 peptides in amyloid beta (A) 42 may be the toxic agent in Alzheimers disease, according to a team from the University of California, Santa Barbara.They report on the process by which the toxic A42 peptides aggregate and...
|
|
|
- PEOPLE - NC Prevention Partners Announces New Board Members
CHAPEL HIL, N.C.- NC Prevention Partners (NCPP) has named three new members to its Board of Directors. Jeffrey Engel, State Health Director; Paula Collins, Senior Policy Advisor, State Board of Education; and Bess Ramey, Senior Account...
|
|
|
OctoPlus' licensee Biolex completes patient enrollment in Phase IIb study with Locteron
-OctoPlus N.V.('OctoPlus') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron,...
|
|
|
BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:0
financial results./ Canada Dial-in Number: 866.272.9941 International Dial-in Number: 617.213.8895 Participant Code: 45596036 Replay Dial-in Number: 888.286.8010 Replay International Dial-in Number: 617.801.6888 Replay Code: 74141589...
|
|
|
Zacks Releases Four Powerful ''Buy'' Stocks: Flanders Corp., Altera Corp., Dr. Reddy's Lab Ltd. and Kinetic Co
CHICAGO-- (BUSINESS WIRE) -- Four free stock picks are being made available today on Zacks.com.The industrys leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Zacks #2 Rank Buy stock for each of the four main...
|
|
|
BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:0
NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 30, at 5:00 p.m. ET ...
|
|
|
PartyLite recognized for service to American Cancer Society
Peg Camp of the American Cancer Society presents the Corporate Community Partner Award to Judi Rogozenski, Steven LaHood and Donna Green of PartyLite, during last weekends eighth annual Relay for Life of Greater Plymouth fundraiser..
|
|
|
BioMarin Pharmaceutical Inc. (BMRN) to Host Second Quarter 2009 Financial Results Conference Call and Webcast
NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 30, at 5:00 p.m.ET (23:00 CET) to discuss second...
|
|
|
BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast
BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m.ET (23:00 CET) NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today...
|
|
|
BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:0
Companies mentioned in this article: BioMarin Pharmaceutical Inc.NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of...
|
|
|
BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:0
NOVATO, Calif., July 1 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.(NASDAQ:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, July 30, at 5...
|
|
|
Percutaneous enterogastric tube dislodgement in tetraplegics
Case reports describing abdominal complications following percutaneous enteral gastric (PEG) tube placement in three tetraplegics.The aim was to increase provider awareness of PEG tube dislodgement as a complication in...
|
|
|
Biolex Therapeutics Announces Completion Of Enrollment In SELECT-2 Phase 2b Trial Of Locteron(R) In Chronic He
Biolex Therapeutics, Inc.announced that it has completed patient enrollment in the SELECT-2 Phase 2b trial of its lead product candidate Locteron for the treatment of chronic hepatitis C. Locteron, controlled-release interferon alpha 2b...
|
|
|
SciClone Pharmaceuticals - Charting A New Course?
(RTTNews) - Shares of SciClone Pharmaceuticals Inc.(SCLN) opened Monday's trading session at $2.65, setting a new 52-week high. Now that it is re-entering the U.S. broad-market Russell 3000 index, the stock is slated to get a higher...
|
|
|
PPD backs away from new facility lease
PPD has cancelled plans to occupy a facility at the North Carolina Research Campus in the US, blaming construction delays which held up the project.The contract research organisation (CRO) had planned to share occupancy of the 160,000 sq....
|
|
|
PPD backs away from new facility lease
PPD has cancelled plans to occupy a facility at the North Carolina Research Campus in the US, blaming construction delays which held up the project.The contract research organisation (CRO) had planned to share occupancy of the 160,000 sq....
|
|
|
SciClone Pharmaceuticals - Charting A New Course?
(RTTNews) - Shares of SciClone Pharmaceuticals Inc.(SCLN) opened Monday's trading session at $2.65, setting a new 52-week high. Now that it is re-entering the U.S. broad-market Russell 3000 index, the stock is slated to get a higher...
|
|
|
OctoPlus' Licensee Biolex Therapeutics Completes Patient Enrollment in Phase IIb Study With Locteron
- OctoPlus N.V.('OctoPlus') (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has completed patient enrollment in its SELECT-2 Phase IIb clinical study of Locteron...
|
|
|
SciClone Pharmaceuticals - Charting A New Course?
Shares of SciClone Pharmaceuticals Inc.(SCLN: News ) opened Monday's trading session at $2.65, setting a new 52-week high. Now that it is re-entering the U.S. broad-market Russell 3000 index, the stock is slated to get a higher...
|
|
|
SciClone Pharmaceuticals - Charting A New Course?
(RTTNews) - Shares of SciClone Pharmaceuticals Inc.(SCLN | Quote | Chart | News | PowerRating) opened Monday's trading session at $2.65, setting a new 52-week high. Now that it is re-entering the U.S. broad-market Russell 3000 index,...
|
|
|
Biolex Therapeutics Announces Completion of Enrollment in SELECT-2 Phase 2b Trial of Locteron(R) in Chronic He
Biolex Therapeutics, Inc.announced today that it has completed patient enrollment in the SELECT-2 Phase 2b trial of its lead product candidate Locteron(R) for the treatment of chronic hepatitis C. Locteron, controlled-release interferon...
|
|
|
Biolex Therapeutics Announces Completion of Enrollment in SELECT-2 Phase 2b Trial of Locteron(R) in Chronic He
Biolex Therapeutics, Inc.announced today that it has completed patient enrollment in the SELECT-2 Phase 2b trial of its lead product candidate Locteron(R) for the treatment of chronic hepatitis C. Locteron, controlled-release interferon...
|
|
|
Denosumab'Great Expectations for Amgen and Osteoporosis Market
Serious side effects like skin infections requiring hospitalization could limit market penetration.Patricia F. Dimond, Ph. An FDA advisory committee will convene on August 13 to discuss, what is considered by some, Amgens fate as a...
|
|
|
Enzon Commences Phase II Trial of PEG-SN38
- Enzon Pharmaceuticals, Inc.(Nasdaq: ENZN) today announced that it has opened its first Phase II trial for PEG-SN38 (EZN-2208), its novel proprietary cancer compound. The trial is open at multiple centers throughout the United...
|
